Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1999 1
2001 1
2004 2
2005 4
2007 3
2010 1
2012 1
2013 1
2014 2
2015 2
2016 2
2017 1
2019 2
2020 2
2021 4
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Response.
Altschul E, Remy-Jardin M, Machnicki S, Sulica R, Raoof S. Altschul E, et al. Among authors: sulica r. Chest. 2020 May;157(5):1394-1395. doi: 10.1016/j.chest.2019.11.053. Chest. 2020. PMID: 32386642 No abstract available.
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Galiè N, et al. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. N Engl J Med. 2015. PMID: 26308684 Free article. Clinical Trial.
Response.
Altschul E, Remy-Jardin M, Sulica R, Raoof S. Altschul E, et al. Among authors: sulica r. Chest. 2020 Feb;157(2):471. doi: 10.1016/j.chest.2019.09.031. Chest. 2020. PMID: 32033649 No abstract available.
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, Grünig E, Jansa P, Klinger JR, Langleben D, McLaughlin VV, Meyer GMB, Ota-Arakaki J, Peacock AJ, Pulido T, Rosenkranz S, Vizza CD, Vonk-Noordegraaf A, White RJ, Chang M, Kleinjung F, Meier C, Paraschin K, Ghofrani HA, Simonneau G; REPLACE investigators. Hoeper MM, et al. Lancet Respir Med. 2021 Jun;9(6):573-584. doi: 10.1016/S2213-2600(20)30532-4. Epub 2021 Mar 24. Lancet Respir Med. 2021. PMID: 33773120 Clinical Trial.
Endpoints for clinical trials of sarcoidosis.
Baughman RP, Drent M, Culver DA, Grutters JC, Handa T, Humbert M, Judson MA, Lower EE, Mana J, Pereira CA, Prasse A, Sulica R, Valyere D, Vucinic V, Wells AU. Baughman RP, et al. Among authors: sulica r. Sarcoidosis Vasc Diffuse Lung Dis. 2012 Oct;29(2):90-8. Sarcoidosis Vasc Diffuse Lung Dis. 2012. PMID: 23461070 Review.
Lung transplantation in interstitial lung disease.
Sulica R, Teirstein A, Padilla ML. Sulica R, et al. Curr Opin Pulm Med. 2001 Sep;7(5):314-22. doi: 10.1097/00063198-200109000-00011. Curr Opin Pulm Med. 2001. PMID: 11584182 Review.
35 results